Donald C Moore, PharmD, BCPS, BCOP, DPLA Pharmacist Clinical Coordinator – Hematology/Oncology Levine Cancer Institute Concord, NC
Erdafitinib (Balversa®, Janssen Products, LP) is a novel fibroblast growth factor receptor (FGFR) inhibitor recently approved by the FDA for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with a susceptible FGFR3 or FGFR2 genetic alteration who have ...